Biomea Fusion Announces First Participant Dosed In 64-Patient OPAL Study Arm Of Icovamenib Plus Low-Dose Semaglutide vs. Semaglutide Alone In Overweight, Obese Adults

Benzinga Newsdesk www.benzinga.com Positive 83.7%

Neg 0% Neu 0% Pos 83.7%

Comments

No comments yet. Be the first!